Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14855852 | 0.87 | PRKCZ (0.49) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL24863513 | 0.84 | PRKCZ (0.50) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL27705854 | 0.84 | ALDH1A1 (0.49) | LMNAL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL1495241 | 0.84 | ALDH1A1 (0.42) | LMNAL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL16590408 | 0.82 | ALDH1A1 (0.46) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL25659898 | 0.82 | PRKCZ (0.45) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL22980415 | 0.82 | PRKCZ (0.51) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL20644257 | 0.81 | CYP4F2 (0.47) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1534068 | 0.81 | LMNA (0.50) | LMNAL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL1495338 | 0.79 | CA12 (0.48) | LMNAL3MBTL1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261327-A1 | 2-(HETEROARYL-THIO)-1-(HETEROARYL)ETHANONE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220298138-A1 | ENZYME INHIBITORS | SYGNATURE DISCOVERY LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | LMNA 728/4885L3MBTL1 1139/4885MAPT 3548/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | LMNA 728/4885L3MBTL1 1139/4885MAPT 3548/4885 |
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | LMNA 1296/4885L3MBTL1 3461/4885MAPT 2404/4885 |
| US-20220298138-A1 | ENZYME INHIBITORS | SERPINB1, CMA1, MAOB | LMNA 1258/4885L3MBTL1 2374/4885MAPT 3406/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | LMNA 728/4885L3MBTL1 1139/4885MAPT 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.